Luke Kempton > Gowling WLG > Birmingham, England > Lawyer Profile

Gowling WLG
TWO SNOWHILL
BIRMINGHAM
B4 6WR
England
Luke Kempton photo

Work Department

Intellectual property.

Position

Partner in the intellectual property team with a particular focus on life sciences; specialises in patent litigation, licensing, collaborations, manufacturing agreements and pharmaceutical regulatory law.

Career

Trained DLA; qualified 1994; partner Wragge & Co LLP 2008; Wragge Lawrence Graham & Co, partner, 2014.

Memberships

Associate of the Chartered Institute of Patent Attorneys (CIPA); Association of the British Pharmaceutical Industry and Biotechnology Industry.

Education

Abingdon School; Leeds University (1986 BSc; 1990 PhD Biochemistry); College of Law, York (1991 CPE; 1992 LPC).

Leisure

Running, cycling, fly fishing, family.

Lawyer Rankings

London > TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious)

The patent practice at Gowling WLG, led by Kate Swaine, is considered ‘a leading IP practice’ by clients, with ‘many bright minds and creative thinkers’. Areas of strength for the team stem from the patent litigation practice, covering the life sciences, manufacturing, engineering and technology sectors, as well as SEP and FRAND strategy and litigation. Clients from the telecoms, hi-tech, and food and beverage industries also trust the team to manage their patent portfolios in a non-contentious capacity. Alexandra Brodie is notable for her SEP/FRAND litigation expertise for telecoms and technology clients, while Paul Inman is a key name in the team for high-profile pharmaceuticals patent infringement and revocation expertise. Luke Kempton and Patrick Duxbury are go-to members of the team for IP transactional work. Also of note is the medical technology team, which fields the ‘excellent’ Jon Ball and ‘superb’ Huw Evans. Life sciences specialist Jenny Davies was recently promoted to partner, while patent litigator and fluent Japanese speaker Seiko Hakada joined the team from Norton Rose Fulbright.